State Board of Administration of Florida Retirement System boosted its stake in shares of AveXis, Inc. (NASDAQ:AVXS) by 19.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,968 shares of the company’s stock after purchasing an additional 2,080 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in AveXis were worth $1,254,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in AVXS. BlackRock Inc. boosted its position in AveXis by 3,055.6% during the 1st quarter. BlackRock Inc. now owns 1,708,386 shares of the company’s stock valued at $129,888,000 after purchasing an additional 1,654,248 shares during the period. Janus Henderson Group PLC acquired a new position in AveXis during the 2nd quarter valued at approximately $55,439,000. Alliancebernstein L.P. boosted its position in AveXis by 4,448.8% during the 2nd quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock valued at $46,418,000 after purchasing an additional 552,546 shares during the period. FMR LLC boosted its position in AveXis by 13.1% during the 2nd quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after purchasing an additional 544,475 shares during the period. Finally, State Street Corp boosted its position in AveXis by 104.2% during the 2nd quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after purchasing an additional 510,189 shares during the period. Institutional investors and hedge funds own 94.96% of the company’s stock.

Several analysts have weighed in on AVXS shares. Sanford C. Bernstein started coverage on AveXis in a research note on Thursday, July 27th. They set an “outperform” rating and a $108.00 target price on the stock. Morgan Stanley started coverage on AveXis in a research note on Thursday, August 3rd. They set an “overweight” rating and a $118.00 target price on the stock. BMO Capital Markets reaffirmed a “buy” rating and set a $123.00 target price on shares of AveXis in a research note on Friday, August 11th. Chardan Capital reaffirmed a “buy” rating and set a $130.00 target price (up previously from $102.50) on shares of AveXis in a research note on Friday, August 11th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $108.00 target price (up previously from $92.00) on shares of AveXis in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. AveXis has a consensus rating of “Buy” and an average target price of $110.67.

In other news, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $101.23, for a total transaction of $1,518,450.00. Following the transaction, the insider now owns 1,841,019 shares in the company, valued at $186,366,353.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction on Friday, September 1st. The shares were sold at an average price of $93.25, for a total value of $165,985.00. Following the transaction, the vice president now owns 1,780 shares in the company, valued at approximately $165,985. The disclosure for this sale can be found here. Insiders have sold 35,340 shares of company stock worth $3,559,683 over the last ninety days. 18.60% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/state-board-of-administration-of-florida-retirement-system-has-1-25-million-position-in-avexis-inc-avxs/1711433.html.

Shares of AveXis, Inc. (NASDAQ AVXS) opened at $97.28 on Friday. AveXis, Inc. has a 52-week low of $44.68 and a 52-week high of $108.27.

AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same period in the prior year, the business earned ($0.87) earnings per share. equities analysts predict that AveXis, Inc. will post -6.23 EPS for the current year.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.